ADC Therapeutics: Pricing of up-sized Initial Public Offering

ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today the pricing of the initial public offering of 12,245,631 shares of its common shares at a price of $19.00 per share.

The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by ADC Therapeutics, are expected to be approximately $232.7 million. The shares are expected to begin trading on the New York Stock Exchange on May 15, 2020 under the ticker symbol “ADCT.” The offering is expected to close on May 19, 2020, subject to customary closing conditions. In addition, ADC Therapeutics has granted the underwriters a 30-day option to purchase up to 1,836,844 additional common shares.

Morgan Stanley, BofA Securities and Cowen are acting as joint book-running managers for the offering.

The offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained, when available, from:

Morgan Stanley & Co. LLC
Attn: Prospectus Department
180 Varick Street
2nd Floor
New York, NY 10014
T +1 866 718 16 49
Order prospectus by email

BofA Securities Inc.
NC1-004-03-43
Attn: Prospectus Department
200 North College Street
3rd floor
Charlotte, NC 28255-0001
Order prospectus by email

Cowen and Company LLC
c/o Broadridge Financial Solutions
Attn: Prospectus Department
1155 Long Island Avenue
Edgewood, NY 11717
T: +1 833 297 29 26
Order prospectus by email